# Claus Berner Møller

> Claus Berner Møller is a Series B investor at ATP backing Health Care and Life Science. See 3 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [ATP](https://shizune.co/investors/profile/atp-23b6)
- Location: Copenhagen, Denmark
- Total investments: 3
- Last investment: Sep 2023
- Lead investor: 33%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/claus-berner-m%C3%B8ller-6751631/?originalSubdomain=dk

Claus Berner Møller is a Vice President, Danish Equities at ATP. Claus Berner Møller attended the University of Copenhagen.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 1 | 33% |
| Life Science | 1 | 33% |
| Medical Device | 1 | 33% |
| Pharmaceutical | 1 | 33% |
| Health Diagnostics | 1 | 33% |

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 1 | 33% |
| Funding Round | 1 | 33% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| MedTrace Pharma | MedTrace develops a hardware platform (MT-100) that automates the production and injection of the gold standard tracer 15O-water into the patient. MedTrace also develops an analytical software platform to interpret the results from the PET scanner.By use of 15O-water, doctors will increase sensitivity in the analysis of the patient while at thesame time increasing patient throughput up to a factor of 4 compared to today's clinical workhorse. | $19M |  | Sep 21, 2023 |  |
| MedTrace Pharma | MedTrace develops a hardware platform (MT-100) that automates the production and injection of the gold standard tracer 15O-water into the patient. MedTrace also develops an analytical software platform to interpret the results from the PET scanner.By use of 15O-water, doctors will increase sensitivity in the analysis of the patient while at thesame time increasing patient throughput up to a factor of 4 compared to today's clinical workhorse. |  |  | May 12, 2021 |  |
| MedTrace Pharma | MedTrace develops a hardware platform (MT-100) that automates the production and injection of the gold standard tracer 15O-water into the patient. MedTrace also develops an analytical software platform to interpret the results from the PET scanner.By use of 15O-water, doctors will increase sensitivity in the analysis of the patient while at thesame time increasing patient throughput up to a factor of 4 compared to today's clinical workhorse. | $29.2M | Series B | May 12, 2021 |  |

3 of 3 investments shown.

## Co-investors
- [Swisscanto Private Equity](https://shizune.co/investors/profile/swisscanto-invest) — VC Fund, 3 deals together
- [BankInvest](https://shizune.co/investors/profile/bankinvest) — VC Fund, 2 deals together
- [European Innovation Council](https://shizune.co/investors/profile/european-innovation-council) — VC Fund, 1 deal together
- [Med Travest](https://shizune.co/investors/profile/med-travest) — VC Fund, 1 deal together
- [Vaekstfonden](https://shizune.co/investors/profile/v%C3%A6kstfonden) — VC Fund, 1 deal together
- [Verve Ventures](https://shizune.co/investors/profile/verve-ventures) — VC Fund, 1 deal together

## About ATP

VC Fund

ATP is a self-governing institution, established by the Folketing by law in 1964. ATP's Board of Directors consists of equal representatives of employers and employees and an independent chairman of the board. The ATP Group has approx. 3,000 employees. ATP is headquartered in Hillerød, customer service centers in Frederikshavn, Holstebro,Haderslev, Vordingborg, Lillerød and Hillerød, as well as offices in Copenhagen, Allerød and New York.

1 contacts available at ATP.

| Name | Title | Profile |
| --- | --- | --- |
| Claus Berner Møller | Vice President | https://shizune.co/investors/profile/claus-berner-m%C3%B8ller |

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does Claus Berner Møller invest in?

Claus Berner Møller invests primarily in Health Care, Life Science and Medical Device startups, most often at Series B and Funding Round stage. Most of the 3 investments tracked by Shizune back companies in Denmark. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Claus Berner Møller last invest?

The most recent investment recorded for Claus Berner Møller closed in Sep 2023. Shizune tracks 3 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co